Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are leaders in their respective therapeutic areas. In 2008 we achieved 11 successful market launches in the United States and the European Union.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
A-Z
A C D E F G L M N P R S T V X Z
|
|
|
 |
Reclast/Aclasta (zoledronic acid/zoledronic acid 5 mg)
|
|
|
|
 |
Afinitor (everolimus) Afinitor (everolimus) tablets have been approved for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. Visit www.afinitor.com/global (non-US residents only) Visit www.afinitor.com (US residents only) |
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.